4521 Stock Overview
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Kaken Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥3,389.00 |
| 52 Week High | JP¥3,890.00 |
| 52 Week Low | JP¥3,161.00 |
| Beta | 0.22 |
| 1 Month Change | -5.73% |
| 3 Month Change | -2.95% |
| 1 Year Change | -8.41% |
| 3 Year Change | -24.27% |
| 5 Year Change | -28.58% |
| Change since IPO | 41.21% |
Recent News & Updates
Shareholder Returns
| 4521 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.0% | 2.7% | 1.8% |
| 1Y | -8.4% | 4.7% | 31.0% |
Return vs Industry: 4521 underperformed the JP Pharmaceuticals industry which returned 4.7% over the past year.
Return vs Market: 4521 underperformed the JP Market which returned 31% over the past year.
Price Volatility
| 4521 volatility | |
|---|---|
| 4521 Average Weekly Movement | 2.0% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4521 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4521's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 1,130 | Hiroyuki Horiuchi | www.kaken.co.jp |
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens.
Kaken Pharmaceutical Co., Ltd. Fundamentals Summary
| 4521 fundamental statistics | |
|---|---|
| Market cap | JP¥128.34b |
| Earnings (TTM) | JP¥2.97b |
| Revenue (TTM) | JP¥72.10b |
43.3x
P/E Ratio1.8x
P/S RatioIs 4521 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4521 income statement (TTM) | |
|---|---|
| Revenue | JP¥72.10b |
| Cost of Revenue | JP¥33.24b |
| Gross Profit | JP¥38.85b |
| Other Expenses | JP¥35.89b |
| Earnings | JP¥2.97b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 78.32 |
| Gross Margin | 53.89% |
| Net Profit Margin | 4.11% |
| Debt/Equity Ratio | 2.7% |
How did 4521 perform over the long term?
See historical performance and comparison